Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)

Completed · Phase 3 · Has a placebo group

Conditions studied: Charcot-Marie-Tooth Disease Type 1A

In brief

The purpose of this study is to determine whether PXT3003 is effective and safe in the treatment of Charcot-Marie-Tooth disease - Type 1 A (CMT1A). This double-blind study will assess in parallel groups 2 doses of PXT3003 compared to Placebo in CMT1A patients treated for 15 months.

Key facts

Study ID

NCT02579759

Run by

Pharnext S.C.A.

People needed

323

Starts

2015-12-01

Expected to finish

2018-08-01

Last updated by the study team

2020-02-27

Who can join

Age: 16 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, aged from 16 to 65 years;
• Patient with a proven genetic diagnosis of CMT1A;
• Mild-to-moderate severity assessed by Charcot-Marie-Tooth Neuropathy Score (version 2) with a score >2 and ≤18;
• Muscle weakness in at least foot dorsiflexion;
• Motor nerve conduction of the ulnar nerve of at least 15 m/sec;
• Providing signed written informed consent to participate in the study and willing and able to comply with all study procedures and scheduled visits.

You may not qualify if…

• Any other associated cause of peripheral neuropathy such as diabetes;
• Patient with another significant neurological disease or a concomitant major systemic disease;
• Clinically significant history of unstable medical illness since the last 30 days (unstable angina, cancer…) that may jeopardize the participation in the study;
• Significant hematologic disease, hepatitis or liver failure, renal failure;
• Limb surgery within six months before randomization or planned before trial completion;
• Clinically significant abnormalities on the pre-study laboratory evaluation, physical evaluation, electrocardiogram (ECG);
• Elevated ASAT/ALAT (> 3 x ULN) and elevated serum creatinine levels (> 1.25 x ULN);
• History of recent alcohol or drug abuse or non-adherence with treatment or other experimental protocols;
• Patient using unauthorized concomitant treatments including but not limited to baclofen, naltrexone, sorbitol (pharmaceutical form), opioids, levothyroxin and potentially neurotoxic drugs such as amiodarone, chloroquine, cancer drugs susceptible to induce a peripheral neuropathy. Patient who can/agrees to stop these medications 4 weeks before randomization and during the whole study duration can be included;
• Female of childbearing potential (apart of patient using adequate contraceptive measures), pregnant or breast feeding;
• Known hypersensitivity to any of the individual components of PXT3003;
• Porphyria as it is a contra indication to baclofen, and it may also induce neuropathy;
• Suspected inability to complete the study follow-up (foreign workers, transient visitors, tourists or any others for whom follow-up evaluation is not assured);
• Limited mental capacity or psychiatric disease rendering the subject unable to provide written informed consent or comply with evaluation procedures;
• Patient who has participated in another trial of investigational drug(s) within the past 30 days;
• If a patient from the same family, living in the same household, has already been included in this study, it will not be possible to include another patient from the same family to avoid mixing of therapeutic units; therefore there would be a risk of inversion of the blind treatments which could jeopardize the interpretation of study results.

Where it is running

• Department of Neurology, Cedars-Sinai Medical Center — Los Angeles, California, United States
• Hospital for Special Care, New Britain — New Britain, Connecticut, United States
• Department of Neurology, McKnight Brain Institute — Gainesville, Florida, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• University of Michigan Health System — Ann Arbor, Michigan, United States
• Department of Neurology, University of Minnesota — Minneapolis, Minnesota, United States
• Department of Neurology and Psichiatry, Saint Louis University — St Louis, Missouri, United States
• Peripheral Neuropathy Center, Neurological Institue Building, Columbia University Medical Center — New York, New York, United States
• Ohio State University — Columbus, Ohio, United States
• Saint Luke's Rehabilitation Institute — Spokane, Washington, United States
• Departement of Neurology, UZ Leuven — Leuven, Belgium
• University Hospital of Quebec — Québec, Quebec, Canada
• Centre de Référence des Maladies Neuromusculaires, Hôpital Swynghedauwl, CHU de Lille — Lille, France
• Centre de Référence des Neuropathies Périphériques Rares, Hôpital Dupuytren, CHU Limoges — Limoges, France
• Service de Neurologie et du Sommeil, CHU Lyon Sud — Lyon, France
• Centre de Référence des Maladies Neuromusculaires, Pôle des Neurosciences Clinique, CHU la Timone — Marseille, France
• Centre de Référence des Maladies Neuromusculaires; Hôtel Dieu, CHU de Nantes — Nantes, France
• Service de Neurologie, Hôpital Kremlin Bicêtre — Paris, France
• Department of Neurology and Institute for Neuropathology, University Hospital RWTH Aachen — Aachen, Germany
• Department of Clinical Neurophysiology, University Medical Center Göttingen — Göttingen, Germany
• Department of Neurology, Ludwig-Maximillian University, Munich — Munich, Germany
• Department for Sleep Medicine and Neuromuscular, University Hospital Münster — Münster, Germany
• Departement of Neurology, Academic Medical Center — Amsterdam, Netherlands
• Department of neurology, Hospital Univesitario de Bellvitge — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.